Abstract:The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets. There is a pressing need for novel drugs, and much hope has been placed on the use of molecular genetics to help define them. However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle. Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-analysis indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk. Linkage analysis has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic aetiology with bipolar disorder. The identification of these loci together with advances in genetic technology, especially the characterisation of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin. Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia. We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant association with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT). The replication of neuregulin 1 association on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 years ago.

Genome-wide approaches to schizophrenia

Genetics of psychiatric disorders in the GWAS era: an update on schizophrenia

Advances in Molecular Genetics of Schizophrenia

The Role of Genetics in the Etiology of Schizophrenia

The genetic architecture of schizophrenia: review of large-scale genetic studies

Progress in the Studies on the Molecular Genetics of Schizophrenia

Genetic Diversity in Schizophrenia: Developmental Implications of Ultra-Rare, Protein-Truncating Mutations

Biological insights from 108 schizophrenia-associated genetic loci

The genetics of schizophrenia: glutamate not dopamine?

Genes for schizophrenia? Recent findings and their pathophysiological implications

Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes

A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation

Identification of Schizophrenia Related Biological Pathways Across Eight Brain Regions

Identification of a Risk Locus at 7p22.3 for Schizophrenia and Bipolar Disorder in East Asian Populations

Integrating Genome-Wide Association Study and Expression Quantitative Trait Locus Study Identifies Multiple Genes and Gene Sets Associated with Schizophrenia

Advances of copy number variation studies in schizophrenia genetics

An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation

Path from schizophrenia genomics to biology: gene regulation and perturbation in neurons derived from induced pluripotent stem cells and genome editing

[Genetic Variation with Increased Risk of Schizophrenia].

P.1.04 Schizophrenia and Cytogenetic Aberrations: in Search of Susceptibility Genes and Pathways

Progress in Genome-Wide Association Studies of Schizophrenia in Han Chinese Populations.